A Phase 2/3 interventional study of LingZhi capsule in Chronic Fatigue Syndrome (CFS) and Post-COVID ME/CFS, sponsored by The University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to participants aged 40 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-09-21.
Sponsored by The University of Hong Kong · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to test if a Lingzhi supplement (CP003) helps people with chronic fatigue or post-COVID fatigue feel better. It will also check if the supplement is safe to use. The main questions it aims to answer are:
Does the Lingzhi supplement reduce fatigue symptoms? Is it safe to take? How does it affect the body's immune system and inflammation?
The investigators will compare people taking the Lingzhi supplement to those who do not receive any treatment (waitlist group) to see if it works.
Participants will:
264 studies on the registry are indexed under Fatigue Syndrome, Chronic; 62 are open to participants now.
This study's planned enrollment of 130 is above the median of 60 across 178 interventional studies indexed under Fatigue Syndrome, Chronic.
Browse Fatigue Syndrome, Chronic studies →The University of Hong Kong is the lead sponsor of 1,292 studies on the registry; 348 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants receive CP003 capsules (5 capsules once daily) for 6 weeks, followed by a 6-week follow-up period.
Drug: LingZhi capsule
Participants initially wait for 6 weeks after randomization without intervention. After the waiting period, participants receive the same CP003 supplement regimen (5 capsules once daily) for 6 weeks, followed by a 6-week follow-up period.
Lingzhi-containing capsules (CP003) is a Chinese Medicine nutritional supplement manufactured by Chinese Pharm Co., Ltd, containing: wild red ganoderma extract, ganoderma spore powder (99.9% broken-wall), β-nicotinamide mononucleotide (NMN), wild yellow ganoderma extract, wild green ganoderma extract, wild purple ganoderma extract, wild white ganoderma extract, wild black ganoderma extract
Mean difference in Chalder Fatigue Score
Likert score 0-4 for 11 items, ranging 0-44, with higher scores indicating greater fatigue
Time frame: From baseline to 6 weeks
Mean difference in Chalder Fatigue Score
Likert score 0-4 for 11 items, ranging 0-44, with higher scores indicating greater fatigue
Time frame: From baseline to 12 weeks
Mean difference in 36-Item Short-Form Health Survey
ranging 0-100, with higher scores indicating better health status
Time frame: from baseline to 6 week and 12 week
Mean difference in Fatigue Severity Score
Likert score 1-7 for 9 items, ranging 9-63, where higher scores indicate more severe fatigue
Time frame: from baseline to 6 week and 12 week
mean difference in Patient Reported Outcome Measurement Information System (PROMIS) Fatigue-Short Form 7A survey
a 5-point Likert scale of 7 items, ranging 0-35, with higher scores indicating greater fatigue
Time frame: from baseline to 6 week and 12 week
Mean difference in hospital anxiety and depression scale
ranging 0-21, with higher scores indicating more severe symptoms
Time frame: from baseline to 6 week and 12 week
Mean difference in Pittsburgh sleep quality index
ranging 0-21, with higher scores indicating worse sleep quality
Time frame: from baseline to 6 week and 12 week visit.
Change in serum markers
for inflammation, immunity and oxidative aging
Time frame: From baseline to 6 weeks
Plan to share: Yes
Supporting information: Study protocol
Ran from Jan 2025 to primary completion in Jan 2026, 12 months.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lingzhi mushroom